This CME Activity has expired and is no longer available for credit.
HER2-Positive Breast Cancer: After Trastuzumab, What's Next?
Time to Complete
November 5, 2012
November 4, 2013
1.00 / AMA PRA Category 1 Credit(s)TM
Jointly sponsored by the Society for Translational Oncology and Massachusetts General Hospital.
Supported through an educational grant from Genentech, Novartis, and Genomic Health
Despite clear evidence regarding the importance of a tumor’s molecular signature in treatment algorithms, too few clinicians routinely obtain such information. This webcast educates clinicians regarding the biochemical pathways that lead to trastuzumab resistance in HER2-positive tumors and current options to overcome such resistance or other options to increase progression-free survival.
Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.
At the end of this online enduring material, participants should be able to:
Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.
It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.
In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.
Beverly Moy, MD, MPH Clinical Director The Breast Oncology Program The MGH Cancer Center Massachusetts General Hospital Assistant Professor in Medicine Harvard Medical School Boston, MA
The following speaker of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Method of Participation: To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.